Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $52.78

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $53.3333.

A number of research firms recently weighed in on ARWR. HC Wainwright boosted their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. Royal Bank Of Canada boosted their target price on Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a report on Wednesday, November 19th. Morgan Stanley upped their price target on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 26th. Bank of America lifted their price objective on Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Finally, Piper Sandler boosted their price objective on Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th.

Arrowhead Pharmaceuticals Stock Up 11.7%

NASDAQ ARWR opened at $68.60 on Tuesday. The business has a fifty day moving average price of $42.71 and a 200 day moving average price of $28.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The company has a market cap of $9.32 billion, a P/E ratio of -857.39 and a beta of 1.28. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $71.50.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the sale, the insider directly owned 212,122 shares in the company, valued at approximately $7,424,270. This trade represents a 8.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mauro Ferrari sold 8,750 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $56.39, for a total transaction of $493,412.50. Following the transaction, the director directly owned 68,764 shares in the company, valued at $3,877,601.96. This trade represents a 11.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 43,750 shares of company stock valued at $1,643,413 in the last three months. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in shares of Arrowhead Pharmaceuticals by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock valued at $553,077,000 after purchasing an additional 510,798 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Arrowhead Pharmaceuticals by 2.8% in the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock valued at $375,941,000 after buying an additional 300,000 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock worth $60,962,000 after buying an additional 2,774,933 shares during the period. Geode Capital Management LLC boosted its stake in Arrowhead Pharmaceuticals by 1.0% during the second quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock worth $47,067,000 after buying an additional 28,193 shares during the period. Finally, T. Rowe Price Investment Management Inc. increased its position in shares of Arrowhead Pharmaceuticals by 0.9% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company’s stock valued at $32,220,000 after acquiring an additional 21,686 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.